Fuyou Liu

Fuyou Liu

Auto-generated profile, based on publicly available information

Fuyou Liu

Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
WYWen-Xia Yang
Wen-Xia Yang
YLYU LIU
YU LIU
SZShu-Min Zhang
Shu-Min Zhang
HWHuafen Wang
Huafen Wang
YLYi-Fei Liu
Yi-Fei Liu
LXLi Xiao
Li Xiao
Tubulointerstitial inflammation plays an important role in the progression of diabetic nephropathy (DN), and tubular epithelial cells (TECs) are crucial promoters of the inflammatory cascade. Exchange protein activated by cAMP (Epac) has been shown to suppress the angiotensin II (Ang-II)-induced release of inflammatory cytokines in tubular cells. However, the role of Epac in TEC-mediated tubulointerstitial inflammation in DN remains unknown. We found that administering the Epac agonist 8-pCPT-2′-O-Me-cAMP (8-O-cAMP) to db/db mice inhibited tubulointerstitial inflammation characterized by macrophage infiltration and increased inflammatory cytokine release and consequently alleviated tubulointerstitial fibrosis in the kidney. Furthermore, 8-O-cAMP administration restored CCAAT/enhancer binding protein β (C/EBP-β) expression and further upregulated the expression of Suppressor of cytokine signaling 3 (SOCS3), while inhibiting p-STAT3, MCP-1, IL-6, and TNF-α expression in the kidney cortex in db/db mice. And in vitro study showed that macrophage migration and MCP-1 expression induced by high glucose (HG, 30 mM) were notably reduced by 8-O-cAMP in human renal proximal tubule epithelial (HK-2) cells. In addition, 8-O-cAMP treatment restored C/EBP-β expression in HK-2 cells and promoted C/EBP-β translocation to the nucleus, where it transcriptionally upregulated SOCS3 expression, subsequently inhibiting STAT3 phosphorylation. Under HG conditions, siRNA-mediated knockdown of C/EBP-β or SOCS3 in HK-2 cells partially blocked the inhibitory effect of Epac activation on the release of MCP-1. In contrast, SOCS3 overexpression inhibited HG-induced activation of STAT3 and MCP-1 expression in HK-2 cells. These findings indicate that Epac activation via 8-O-cAMP ameliorates tubulointerstitial inflammation in DN through the C/EBP-β/SOCS3/STAT3 pathway.

24 July 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
HZHao Zhao
Hao Zhao
NJNa Jiang
Na Jiang
YHYachun Han
Yachun Han
MYMing Yang
Ming Yang
PGPeng Gao
Peng Gao
LSLin Sun
Lin Sun
Renal tubulointerstitial fibrosis (TIF) is a common pathological feature of aristolochic acid (AA) nephropathy (AAN). G2/M arrest of proximal tubular cells (PTCs) is implicated in renal fibrosis of AAN, but the upstream regulatory molecule remains unknown. Hypoxia inducible factor‐1α (HIF‐1α) promotes renal fibrosis in kidney disease, but the role of HIF‐1α in AAN is unclear. Evidence shows that HIF‐1α and p21, a known inducer of cellular G2/M arrest, are closely related to each other. To investigate the role of HIF‐1α in renal fibrosis of AAN and its effects on p21 expression and PTCs G2/M arrest, mice with HIF‐1α gene knockout PTCs (PT‐HIF‐1α‐KO) were generated, and AAN was induced by AA. In vitro tests were conducted on the human PTCs line HK‐2 and primary mouse PTCs. HIF‐1α and p21 expression, fibrogenesis, and G2/M arrest of PTCs were determined. Results showed that HIF‐1α was upregulated in the kidneys of wild‐type (WT) AAN mice, accompanied by p21 upregulation, PTCs G2/M arrest and renal fibrosis, and these alterations were reversed in PT‐HIF‐1α‐KO AAN mice. Similar results were observed in HK‐2 cells and were further confirmed in primary PTCs from PT‐HIF‐1α‐KO and WT mice. Inhibiting p21 in HK‐2 cells and primary PTCs did not change the expression of HIF‐1α, but G2/M arrest and fibrogenesis were reduced. These data indicate that HIF‐1α plays a key role in renal fibrosis in AAN by inducing PTCs G2/M arrest modulated through p21. HIF‐1α may serve as a potential therapeutic target for AAN.

19 March 2019 in Nephrology
Verified
Journal Article
Open access
PDF file
HTHanfen Tang
Hanfen Tang
XZXuping Zhu
Xuping Zhu
CGCai Gong
Cai Gong
HLHaiyang Liu
Haiyang Liu
FLFuyou Liu
Fuyou Liu
Aim: This study was conducted to investigate the chronic injury of peritoneal glucose injection on the peritoneum and intestine and the protective effects of omega‐3 polyunsaturated fatty acid (ω‐3PUFA) during peritoneal dialysis (PD).Methods: Peritoneal dialysis animal models were established by intraperitoneal injection of 4.25% glucose for 28 days. Protein expression in ileum and peritoneum was measured by immunofloresence and immunohistochemistry. Protein expression in macrophages was measured by Western blot. Fibrosis was analyzed by Masson staining.Results: Peritoneal dialysis significantly increased the structural injury and decreased junction‐related protein ZO‐1 and occludin expression in ileum, the expression of proteins relating to the activation of M2 (Erg2, IRF4), but not M1 (CD38, IRF5) macrophages. PD significantly increased the expression of TGF‐β1, VEGF and ALK5 protein in peritoneal tissues. PD significantly increased fibrosis (Masson staining) and the expression of fibroblast marker α‐SMA in peritoneal tissues. Injection of macrophage clean reagent and ω‐3PUFA significantly inhibited M2 activation, and decreased Masson staining, α‐SMA, TGF‐β1, VEGF and ALK5 protein expression in peritoneal tissues in PD treated rats. ω‐3PUFA injection significantly decreased PD‐induced injury in ileum and normalized the expression of ZO‐1 and occludin in the ileum of PD rats.Conclusion: Omega‐3 fatty acids can provide a protective role on PD‐induced peritoneal fibrosis and injury of the intestine.

1 September 2013 in Microvascular Research
Verified
Journal Article
Open access
GCGuochun Chen
Guochun Chen
HLHong Liu
Hong Liu
FLFuyou Liu
Fuyou Liu
Patients with nephrotic syndrome (NS) carry a high risk of venous thromboembolism (VTE) due to the abnormalities in coagulation and fibrinolysis. Although massive urine protein loss is considered to trigger the cascade of hypercoagulation, the exact nature of VTE in NS patients still remains obscure, especially in some cases when VTE occurs far before the presence of nephrotic proteinuria. Recent findings illustrate that loss of local glomerular homeostasis, like disturbance of cytokine profiles in endothelial cells or aberrant cellular crosstalks in glomerulus, is sufficient to initiate the development of thrombotic disease in glomerulonephropathy. Emerging data have highlighted the glomerular endothelial cell as a key regulator of local homeostasis, which might mediate the haemostatic derangement in the beginning of glomerular disease by expression of numerous prothrombotic factors and result in the subsequent predilection of VTE in NS. As the glomerulus-derived circulating factors are all collected and flushed into the renal vein directly, it is reasonable to suggest that increased release of glomerulus-derived thrombotic regulators, particularly from endothelial cells, may play a significant role in the highest proclivity for the renal vein as the site of thrombosis in NS. In this review, we thus discuss the current understandings of thromboembolism in NS with focus on how the glomerular endothelial cell involves in the pathogenesis of VTE, which may help to increase our understandings in the anti-thrombotic therapy for patients with NS.

17 December 2013 in Nephrology
Verified
Journal Article
Open access
PDF file
SYShikun Yang
Shikun Yang
LXLi Xiao
Li Xiao
PSPan‐Ai Song
Pan‐Ai Song
XXXiao‐Xuan Xu
Xiao‐Xuan Xu
FLFu‐You Liu
Fu‐You Liu
LSLin Sun
Lin Sun
The heavy metal lead (Pb) is a major environmental and occupational hazard. Epidemiological studies have demonstrated a strong association between lead exposure and the presence of chronic kidney injury. Some studies have suggested that chelation therapy with calcium disodium ethylenediaminetetraacetic acid (calcium disodium EDTA) might help decrease the progression of chronic kidney disease among patients with measurable body lead burdens. However, calcium disodium EDTA chelation in lead exposure is controversial due to the potential for adverse effects such as acute tubular necrosis. Therefore, we investigated the available randomized controlled trials assessing the renoprotective effects of calcium disodium EDTA chelation therapy. Our meta‐analysis shows that calcium disodium EDTA chelation therapy can effectively delay the progression of chronic kidney disease in patients with measurable body lead burdens reflected by increasing the levels of estimated glomerular filtration rate (eGFR) and creatinine clearance rate (Ccr). There appears to be no conclusive evidence that calcium disodium EDTA can decrease proteinuria.

8 June 2012 in Renal Failure
Verified
Journal Article
Open access
LZLetian Zhou
Letian Zhou
YLYing Li
Ying Li
FLFuyou Liu
Fuyou Liu
YPYouming Peng
Youming Peng
YLYinghong Liu
Yinghong Liu
JLJun Li
Jun Li
Acute tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare disease usually having a good prognosis. But the recurrence of uveitis and the chronic progression of kidney injury are still main problems. We report a 15-year-old girl with TINU who showed proteinuria, pathological renal change, multiple organ dysfunction, and immune disorders. After 2 months of 1 mg/kg/day corticosteroid therapy, 24-h urine protein, liver function tests, and creatine kinase returned to normal level. In spite of this, steroid was tapered off slowly and small dose of steroid maintenance therapy lasted for 1 year. Her kidney and ocular symptoms did not recur during 5 years of follow-up. We suggest low-dose steroid maintenance therapy to decrease the recurrence of the TINU syndrome.